141 related articles for article (PubMed ID: 38530080)
1. Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review.
Xiong W; Yang Z; Chen Y
Immunotherapy; 2024 Mar; ():. PubMed ID: 38530080
[TBL] [Abstract][Full Text] [Related]
2. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
Ai Q; Chen W; Li Y; Li G
Front Immunol; 2022; 13():840916. PubMed ID: 35720298
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-associated gastritis: Patterns and management.
Lin J; Lin ZQ; Zheng SC; Chen Y
World J Gastroenterol; 2024 Apr; 30(14):1941-1948. PubMed ID: 38681126
[TBL] [Abstract][Full Text] [Related]
4. Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review.
Sugiyama Y; Tanabe H; Matsuya T; Kobayashi Y; Murakami Y; Sasaki T; Kunogi T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Tanino M; Mizukami Y; Fujiya M; Okumura T
Endosc Int Open; 2022 Jul; 10(7):E982-E989. PubMed ID: 35845030
[No Abstract] [Full Text] [Related]
5. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
6. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
7. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
[TBL] [Abstract][Full Text] [Related]
8. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract][Full Text] [Related]
10. The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors.
Simmons D; Lang E
Cureus; 2017 Oct; 9(10):e1774. PubMed ID: 29250474
[TBL] [Abstract][Full Text] [Related]
11. Kikuchi disease: A case report about Sintilimab-induced Kikuchi histiocytic necrotizing lymphadenitis and literature review.
Ren C; Wang Y; Yang X; Tuo Y; Li Y; Gong J
Heliyon; 2024 May; 10(9):e30608. PubMed ID: 38742085
[TBL] [Abstract][Full Text] [Related]
12. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
Bello E; Cohen JV; Mino-Kenudson M; Dougan M
J Immunother Cancer; 2019 Feb; 7(1):41. PubMed ID: 30744698
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
14. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
15. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
16. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
17. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
18. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
19. Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress.
Ji H; Wen Z; Liu B; Chen H; Lin Q; Chen Z
Front Immunol; 2022; 13():995121. PubMed ID: 36091070
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease.
Irshaid L; Robert ME; Zhang X
Arch Pathol Lab Med; 2021 Feb; 145(2):191-200. PubMed ID: 33501492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
